A variety of pharmacologic inhibitors of glycolysis have shown promise in animal models of autoimmune disease, including 2‐deoxyglucose, inhibitors of the glucose transporter GLUT1, and dichloroacetate, which is an inhibitor of the enzyme PDHK1. The gene discussed is SLC2A1; the disease is autoimmune disease.